Australia's ImpediMed soars on tie-up to provide breast cancer screening services
04/10/2022 01:34
** Shares of ImpediMed Ltd IPD.AX jump as much as 9.4% to
A$0.07, recording their biggest intraday pct gain since Aug. 3
** Medical software tech firm says signed strategic
commercial partnership and pilot programme with U.S.-based
cancer care service provider GenesisCare urn:newsml:reuters.com:*:nASXbKZD2w
** Partnership to provide lymphoedema screening services for
breast cancer patients in centres across the United States
urn:newsml:reuters.com:*:nASXbKZD2w
** Says pilot programme will consist of initial roll-out of
five SOZO units
** SOZO is co's FDA-approved medical device used to test
heart failure, lymphoedema, and protein calorie malnutrition
** Stock hits highest level since Sept. 23
** Over 1.3 mln shares change hands, more than double the
30-day average volume
** Stock down 63.4% this year, as of last close
(Reporting by Poonam Behura in Bengaluru)
((Poonam.Behura@thomsonreuters.com;))